Sunitinib Accord

sunitinib

Table of contents

Opinion

On 10 December 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Sunitinib Accord, intended for the treatment of cancer. The applicant for this medicinal product is Accord Healthcare S.L.U.

Sunitinib Accord will be available as 12.5, 25, 37.5 and 50 mg hard capsules. The active substance of Sunitinib Accord is sunitinib, an antineoplastic agent – a protein-tyrosine kinase inhibitor (ATC code: L01XE04), which inhibits multiple receptor tyrosine kinases that are implicated in tumour growth, pathologic angiogenesis, and metastatic progression of cancer.

Sunitinib Accord is a generic of Sutent, which has been authorised in the EU since 19 July 2006. Studies have demonstrated the satisfactory quality of Sunitinib Accord, and its bioequivalence to the reference product Sutent.

The full indication is:

Sunitinib Accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib treatment due to resistance or intolerance.

Sunitinib Accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (MRCC) in adults.

Sunitinib Accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pNET) with disease progression in adults.

Sunitinib Accord should be prescribed by physicians experienced in the treatment of cancer.

Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR) and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

Key facts

Name
Sunitinib Accord
Agency product number
EMEA/H/C/005419
International non-proprietary name (INN) or common name
  • sunitinib
Active substance
  • sunitinib
Therapeutic area
Gastrointestinal Stromal Tumors
Carcinoma, Renal Cell
Neuroendocrine Tumors
Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Date opinion adopted
10/12/2020
Company name
Accord Healthcare S.L.U.
Status
Positive
Application type
Initial authorisation

More information on Sunitinib Accord

How useful was this page?

Add your rating
Average
1 rating